+41 91 682 20 40 info@elixi-int.com

ABOUT US

We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.

Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value.

 

QUALITY

As a pharmaceutical wholesaler, working directly with pharma manufactures, medicine distributors, hospitals and clinics, we comply with the newest Standard Operating Procedures (SOPs), which guide our professional team step-by-step in all of ELIXI’s activities ensuring the highest quality standards required by the pharma world.

> Read more

 

WHO WE ARE

We deliver pharma products from Switzerland and from all over the world.

Our team in ELIXI International has a solid experience in the distribution of medical products.

History has taught us to prioritize the urgency that lays behind the need of supplying a drug in the fastest possible way. Here in ELIXI we consider fast delivery as a basic but mandatory human value. In order to achieve this goal, we developed a simple but qualified process made of synergies with long lasting partners who, like us, believe in people and not in machines.

 

NEWS

New indication for Dupixent (dupilumab) as add on treatment for patients with severe asthma

EMA’s human medicines committee (CHMP) has recommended granting an extension of indication to Dupixent (dupilumab) as an add-on maintenance treatment for adult…

read more

Ondexxya (andexanet alfa), first antidote for reversal of anticoagulation with factor Xa inhibitors apixaban and rivaroxaban

EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation in the European Union for Ondexxya (andexanet alfa). This medicine…

read more

Waylivra (volanesorsen), first treatment for rare disease characterised by high levels of triglycerides in blood

The European Medicines Agency has recommended granting a conditional marketing authorisation (CMA) for Waylivra (volanesorsen), the first medicine for the treatment of…

read more

Palynziq (pegvaliase), new treatment for phenylketonuria, a rare inherited metabolic disease

EMA’s human medicines committee (CHMP) has recommended the authorisation of Palynziq (pegvaliase), a new medicine for patients aged 16 and…

read more

Zynquista (sotagliflozin), New add-on treatment to insulin for treatment of certain patients with type 1 diabetes

EMA’s human medicines committee (CHMP) has adopted a positive opinion for Zynquista (sotagliflozin) intended as an adjunct to insulin for…

read more

The World Health Organisation issues an alert on falsified ICLUSIG traded globally

The Medical Product Alert relates to confirmed falsified versions of ICLUSIG 15mg and ICLUSIG 45mg circulating in the WHO Region…

read more

Forxiga and Edistride (Dapagliflozin) recommended by EMA as first oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes

EMA’s human medicines committee (CHMP) has recommended for the first time an adjunct treatment to insulin in the form of…

read more

Cablivi (caplacizumab-yhdp) approved by FDA for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)

The U.S. Food and Drug Administration has approved Cablivi (caplacizumab-yhdp) injection, the first therapy specifically indicated, in combination with plasma…

read more

First generic version of Sabril ( vigabatrin) approved by FDA for the treatment of complex partial seizures

The U.S. Food and Drug Administration approved the first generic version of Sabril (vigabatrin) 500 mg tablets for treating complex…

read more

Ultomiris (ravulizumab), approved by FDA for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)

The U.S. Food and Drug Administration has approved Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal…

read more

European Commission Approves Merck’s DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen for the Treatment of HIV-1 in Appropriate Patients

Delstrigo is an antiviral medicine used to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that…

read more

FDA approves Elzonris (tagraxofusp-erzs), first treatment for rare blood disease

The U.S. Food and Drug Administration has approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm…

read more

CONTACT US

ELIXI International SA

 

Vicolo Oldelli 1
6830 Chiasso / Switzerland

Tel./Fax +41 91 6822040

Your name (required)

Your e-mail (required)

Your message